Prostate Cancer News
Brothers of Prostate Cancer Patients Undergo More Diagnostic Testing (September 7, 2010)Some of the elevated risk of prostate cancer among those with a family history of the disease may be due to increased prostate cancer testing and detection in this population. These findings were recently published in the Journal of the National Cancer... Continue Reading
Death from Other Causes Among Men with Early-stage Prostate Cancer (August 26, 2010)Among men with early-stage prostate cancer, assessment of other health problems may help guide prostate cancer treatment decisions; men who are likely to die of causes other than prostate cancer may not benefit from aggressive prostate cancer treatment.... Continue Reading
Study Evaluates Physician Use of Finasteride for Prostate Cancer Prevention (August 18, 2010)Recent research indicates that 64% of urologists and 80% of primary care physicians surveyed do not prescribe finasteride for prevention of prostate cancer in high-risk men. These findings were recently published in the journal Cancer Epidemiology, Biomarkers... Continue Reading
Provenge® for Hormone-refractory Prostate Cancer (August 11, 2010)Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine.[1] The... Continue Reading
Study Explores Prostate Cancer Among Men with Low PSA Levels (July 30, 2010)In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters... Continue Reading
Statins May Reduce Risk of Prostate Cancer Recurrence (July 2, 2010)Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.[1] Statins are cholesterol-lowering drugs; they are the most commonly prescribed... Continue Reading
Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (June 30, 2010)Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.[1] Men with early-stage... Continue Reading
Jevtana Approved for Hormone-refractory Prostate Cancer (June 21, 2010)Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen. Prostate... Continue Reading
Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (June 8, 2010)The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented... Continue Reading
External Beam Radiation Raises Risk of Hip Fracture in Prostate Cancer (June 8, 2010)Men treated with external beam radiation therapy for prostate cancer may have an increased risk of hip fracture, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association. Radiation therapy is a commonly... Continue Reading
Latest Prostate Cancer News By Stage
Screening and Prevention
Brothers of Prostate Cancer Patients Undergo More Diagnostic Testing (September 7, 2010)
Some of the elevated risk of prostate cancer among those with a family history of the disease may be due to increased prostate cancer testing and detection in this population. These findings were recently published in the Journal of the National Cancer... Continue Reading
Study Evaluates Physician Use of Finasteride for Prostate Cancer Prevention (August 18, 2010)Recent research indicates that 64% of urologists and 80% of primary care physicians surveyed do not prescribe finasteride for prevention of prostate cancer in high-risk men. These findings were recently published in the journal Cancer Epidemiology, Biomarkers... Continue Reading
Dogs May Be Able to Smell Prostate Cancer (June 8, 2010)Dogs may be able to smell the presence of prostate cancer in patient urine samples, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association (AUA). Volatile organic compounds (VOCs) are organic chemical... Continue Reading
PCA3 a More Specific Test for Prostate Cancer (June 4, 2010)For the detection of prostate cancer, a new urine test known as PCA3 produces fewer false-positive test results than the commonly used prostate-specific antigen (PSA) blood test. These results were presented at the 2010 annual meeting of the American... Continue Reading
Prostate Cancer and the Increased Risk of Blood Clots (April 23, 2010)Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.[1] In general,... Continue Reading
More Screening and PreventionEarly Stage I-II (A-B)
Death from Other Causes Among Men with Early-stage Prostate Cancer (August 26, 2010)
Among men with early-stage prostate cancer, assessment of other health problems may help guide prostate cancer treatment decisions; men who are likely to die of causes other than prostate cancer may not benefit from aggressive prostate cancer treatment.... Continue Reading
Study Explores Prostate Cancer Among Men with Low PSA Levels (July 30, 2010)In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters... Continue Reading
Statins May Reduce Risk of Prostate Cancer Recurrence (July 2, 2010)Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.[1] Statins are cholesterol-lowering drugs; they are the most commonly prescribed... Continue Reading
Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (June 30, 2010)Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.[1] Men with early-stage... Continue Reading
External Beam Radiation Raises Risk of Hip Fracture in Prostate Cancer (June 8, 2010)Men treated with external beam radiation therapy for prostate cancer may have an increased risk of hip fracture, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association. Radiation therapy is a commonly... Continue Reading
More Early Stage I-II (A-B)Locally Advanced Stage III (C)
Study Explores Prostate Cancer Among Men with Low PSA Levels (July 30, 2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters... Continue Reading
Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (June 8, 2010)The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented... Continue Reading
Prostate Cancer and the Increased Risk of Blood Clots (April 23, 2010)Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.[1] In general,... Continue Reading
Neoadjuvant Chemotherapy for High-risk Localized Prostate Cancer Is Safe and Effective (March 19, 2010)Neoadjuvant treatment with Taxotere® (docetaxel) and Emcyt® (estramustine) for high-risk localized prostate cancer appears to be safe and produces promising responses compared with standard treatment, according to the results of a Phase III randomized... Continue Reading
Addition of Androgen Deprivation Therapy Improves Survival with Locally Advanced Prostate Cancer (October 8, 2009)In men with locally advanced prostate cancer, the addition of androgen deprivation therapy to radiation therapy improves overall and progression-free survival without substantially affecting cardiovascular mortality. These results, based on close to 10... Continue Reading
More Locally Advanced Stage III (C)Metastatic Stage IV (D)
Provenge® for Hormone-refractory Prostate Cancer (August 11, 2010)
Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine.[1] The... Continue Reading
Study Explores Prostate Cancer Among Men with Low PSA Levels (July 30, 2010)In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters... Continue Reading
Prostate Cancer and the Increased Risk of Blood Clots (April 23, 2010)Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.[1] In general,... Continue Reading
Targeted Agents plus Chemotherapy Effective for Hormone-refractory Prostate Cancer (April 7, 2010)The combination of Avastin® (bevacizumab), Thalomid® (thalidomide), and Taxotere® (docetaxel) is highly active in hormone-refractory prostate cancer, according to the results of a study published early online in the Journal of Clinical Oncology.[1] The... Continue Reading
Provenge® Prolongs Survival in Hormone Refractory Prostate Cancer (March 22, 2010)The immunotherapy agent Provenge® (sipuleucel-T) significantly prolongs overall survival in men with metastatic, hormone-refractory prostate cancer, according to follow-up data presented at the 2010 Genitourinary Cancers Symposium in San Francisco.... Continue Reading
More Metastatic Stage IV (D)Refactory/Recurrent
Jevtana Approved for Hormone-refractory Prostate Cancer (June 21, 2010)
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen. Prostate... Continue Reading
Provenge Approved for Advanced Prostate Cancer (April 30, 2010)Provenge® (sipuleucel-T), a type of immunotherapy, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of asymptomatic or minimally symptomatic, metastatic, hormone-refractory prostate cancer.[1] Prostate cancer is... Continue Reading
Investigational Drug Shows Activity in Advanced Prostate Cancer (April 26, 2010)An investigational anti-androgen drug called MDV3100 has shown encouraging anti-tumor activity in patients with progressive, metastatic, hormone-resistant prostate cancer, according to the preliminary results of a study published early online in the... Continue Reading
Prostate Cancer and the Increased Risk of Blood Clots (April 23, 2010)Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.[1] In general,... Continue Reading
Targeted Agents plus Chemotherapy Effective for Hormone-refractory Prostate Cancer (April 7, 2010)The combination of Avastin® (bevacizumab), Thalomid® (thalidomide), and Taxotere® (docetaxel) is highly active in hormone-refractory prostate cancer, according to the results of a study published early online in the Journal of Clinical Oncology.[1] The... Continue Reading
<More Refactory/Recurrent